Oncolys BioPharma Inc. (TYO:4588)

Japan · Delayed Price · Currency is JPY

6,830.00

+340.00 (5.24%)

Oct 6, 2026, 3:30 PM JST

Market Cap	201.39B +1,095.4%
Revenue (ttm)	28.55M -9.0%
Net Income	-2.06B
EPS	-82.55
Shares Out	29.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,690,100
Open	6,520.00
Previous Close	6,490.00
Day's Range	6,420.00 - 7,020.00
52-Week Range	668.00 - 6,980.00
Beta	1.06
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2026

About Oncolys BioPharma

Oncolys BioPharma Inc. engages in the research, development, manufacturing, sale, and import of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the United States, and Asia. Its product pipeline comprises Telomelysin (OBP-301), an oncolytic viral immunotherapy which is in phase II clinical trial to treat gastric cancer; phase I clinical trial for the treatment of HCC; and treatment of esophageal cancer. The company also develops OBP-601(Censavudine), which is in phase II clinical trial to treat progressive supranucl... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2004

Employees 45

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4588

Full Company Profile

Financial Performance

In 2024, Oncolys BioPharma's revenue was 31.38 million, a decrease of -50.21% compared to the previous year's 63.04 million. Losses were -1.68 billion, -13.09% less than in 2023.

Financial Statements